Copy to clipboard 
Aurora Spine introduced Aurora Biologics, a new division dedicated to advancing spinal fusion success through biologic innovation.
The 100% allograft bone solutions include:
- TURBO FUSE Fiber Putty – a bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment.
- OSTEO GRAFT DBM Putty – a demineralized cortical bone graft with a cohesive, moldable consistency to support bone formation without synthetic carriers.
- OSTEO BRIDGE Sponge Strips – a sponge-like bone graft substitute that conforms to patient anatomy and fills bone voids to support structural regeneration.
Each biologic is free of synthetic carriers, delivering natural osteoconductive and osteoinductive properties for predictable, high-quality bone growth. Fully moldable and cohesive, these materials are designed to fill bony defects or augment fusion sites, providing a natural biologic scaffold for bone regeneration.
“Aurora Biologics completes our strategy of providing customers with a seamless, fully integrated portfolio,” said Mathew Goldstone, Chief Commercial Officer of Aurora Spine. “Each of our mechanical fusion systems—whether lumbar, SI, or cervical—is designed to promote bone growth. With the addition of Aurora Biologics, we now enhance the healing phase as well, allowing surgeons to deliver a fully optimized fusion procedure from start to finish.”
“Our new Aurora Biologics platform not only reinforces our commitment to improved clinical outcomes but also serves as a strong growth catalyst,” said Trent J. Northcutt, President & CEO of Aurora Spine. “By integrating biologics across our minimally invasive product portfolio, we anticipate more than a 30 percent increase over prior biologic offerings—driving stronger margins and creating a powerful new profit engine for Aurora Spine.”
Source: Aurora Spine Corporation
Aurora Spine introduced Aurora Biologics, a new division dedicated to advancing spinal fusion success through biologic innovation.
The 100% allograft bone solutions include:
TURBO FUSE Fiber Putty – a bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment.
OSTEO GRAFT DBM...
Aurora Spine introduced Aurora Biologics, a new division dedicated to advancing spinal fusion success through biologic innovation.
The 100% allograft bone solutions include:
- TURBO FUSE Fiber Putty – a bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment.
- OSTEO GRAFT DBM Putty – a demineralized cortical bone graft with a cohesive, moldable consistency to support bone formation without synthetic carriers.
- OSTEO BRIDGE Sponge Strips – a sponge-like bone graft substitute that conforms to patient anatomy and fills bone voids to support structural regeneration.
Each biologic is free of synthetic carriers, delivering natural osteoconductive and osteoinductive properties for predictable, high-quality bone growth. Fully moldable and cohesive, these materials are designed to fill bony defects or augment fusion sites, providing a natural biologic scaffold for bone regeneration.
“Aurora Biologics completes our strategy of providing customers with a seamless, fully integrated portfolio,” said Mathew Goldstone, Chief Commercial Officer of Aurora Spine. “Each of our mechanical fusion systems—whether lumbar, SI, or cervical—is designed to promote bone growth. With the addition of Aurora Biologics, we now enhance the healing phase as well, allowing surgeons to deliver a fully optimized fusion procedure from start to finish.”
“Our new Aurora Biologics platform not only reinforces our commitment to improved clinical outcomes but also serves as a strong growth catalyst,” said Trent J. Northcutt, President & CEO of Aurora Spine. “By integrating biologics across our minimally invasive product portfolio, we anticipate more than a 30 percent increase over prior biologic offerings—driving stronger margins and creating a powerful new profit engine for Aurora Spine.”
Source: Aurora Spine Corporation
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
